{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-052460","form_type":"8-K","ticker":null,"cik":"0001840748","company_name":"LAVA Therapeutics NV","filed_at":"2025-05-23T23:59:59+00:00","discovered_at":"2026-05-14T18:02:50.071608+00:00","generated_at":"2026-05-20T15:23:45.455469+00:00","sec_items":["4.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"LAVA Therapeutics appoints KPMG as new auditor, dismisses PwC","bullets":["Board approved KPMG as independent auditor for FY2025, dismissing PwC effective May 20, 2025.","PwC's reports for FY2023 and FY2024 were unqualified, with no adverse opinions or modifications.","No accounting disagreements with PwC; prior material weaknesses in IT controls and segregation of duties were remediated as of Dec 31, 2024.","PwC's letter agreeing with the statements is filed as Exhibit 16.1."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-052460","json":"https://secwatch.observer/filing/0001104659-25-052460.json","markdown":"https://secwatch.observer/filing/0001104659-25-052460.md","text":"https://secwatch.observer/filing/0001104659-25-052460.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1840748/000110465925052460/0001104659-25-052460-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1840748/000110465925052460/tm2515950d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-20T15:23:45.455469+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"134e1d03df41c9911a32702693f5189372753911","claim":"LAVA Therapeutics NV engaged KPMG LLP as its auditor.","evidence_excerpt":"On May 20, 2025, the board of directors (the \"Board\") of LAVA Therapeutics N.V. (the \"Company\"), upon the recommendation of the audit committee of the Board (the \"Audit Committee\"), approved the appointment of KPMG LLP (\"KPMG\") as the Company's independent registered public accounting firm to audit the Company's U.S. GAAP consolidated financial statements for the fiscal year ending December 31, 2025, and dismissed PricewaterhouseCoopers Accountants N.V. (\"PwC\").","evidence_source":"SEC 8-K Item 4.01/4.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1840748/000110465925052460/0001104659-25-052460-index.htm","confidence":0.99,"family_label":"Auditor Changes","details":[{"label":"Action","value":"engagement"},{"label":"Auditor","value":"KPMG LLP"}],"fact_type":"auditor_change"},{"claim_id":"bbc48a8fd1202ea1382cafdf2b950de9617d83a9","claim":"LAVA Therapeutics NV dismissed PricewaterhouseCoopers Accountants N.V. as its auditor.","evidence_excerpt":"On May 20, 2025, the board of directors (the \"Board\") of LAVA Therapeutics N.V. (the \"Company\"), upon the recommendation of the audit committee of the Board (the \"Audit Committee\"), approved the appointment of KPMG LLP (\"KPMG\") as the Company's independent registered public accounting firm to audit the Company's U.S. GAAP consolidated financial statements for the fiscal year ending December 31, 2025, and dismissed PricewaterhouseCoopers Accountants N.V. (\"PwC\").","evidence_source":"SEC 8-K Item 4.01/4.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1840748/000110465925052460/0001104659-25-052460-index.htm","confidence":0.99,"family_label":"Auditor Changes","details":[{"label":"Action","value":"dismissal"},{"label":"Auditor","value":"PricewaterhouseCoopers Accountants N.V."},{"label":"Successor","value":"KPMG LLP"}],"fact_type":"auditor_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}